Blog

Insights from Guy Levy-Yurista, PhD – CEO of Synthace. About Guy: CEO of Synthace, a company that UKI2S has been supporting since investing at seed stage, now post series C having recently raised $35m Israeli-American with a Physics PhD and a Wharton MBA with 20 years of experience in both start-up and Fortune 500 environments […]

read more

Against the challenging backdrop of a global pandemic, 2020 saw the successful merger of UKI2S portfolio company Perfectus Biomed and US-based Extherid Biosciences. There are of course specific challenges for a UK/US merger, but the value of cross-cultural collaboration across all levels of the business should be celebrated particularly for the personal growth and development […]

read more

Completing a UK/US merger can be a complicated and demanding undertaking at the best of times, let alone during a global pandemic. However, for UKI2S portfolio company Perfectus Biomed, and US-based Extherid Biosciences, this unique situation brought unforeseen advantages. We spoke to Sam Westgate, CEO, Perfectus Biomed, and Marnie Peterson, CEO, Extherid Biosciences, to learn […]

read more

1 2